BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1464 related articles for article (PubMed ID: 12538684)

  • 61. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism.
    Blazar BR; Carreno BM; Panoskaltsis-Mortari A; Carter L; Iwai Y; Yagita H; Nishimura H; Taylor PA
    J Immunol; 2003 Aug; 171(3):1272-7. PubMed ID: 12874215
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The function of donor versus recipient programmed death-ligand 1 in corneal allograft survival.
    Shen L; Jin Y; Freeman GJ; Sharpe AH; Dana MR
    J Immunol; 2007 Sep; 179(6):3672-9. PubMed ID: 17785803
    [TBL] [Abstract][Full Text] [Related]  

  • 63. High-level expression of B7-H1 molecules by dendritic cells suppresses the function of activated T cells and desensitizes allergen-primed animals.
    Kim HK; Guan H; Zu G; Li H; Wu L; Feng X; Elmets C; Fu Y; Xu H
    J Leukoc Biol; 2006 Apr; 79(4):686-95. PubMed ID: 16461745
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade.
    Reynoso ED; Elpek KG; Francisco L; Bronson R; Bellemare-Pelletier A; Sharpe AH; Freeman GJ; Turley SJ
    J Immunol; 2009 Feb; 182(4):2102-12. PubMed ID: 19201863
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Modulation of CD4⁺ T cell responses following splenectomy in hepatitis C virus-related liver cirrhosis.
    Hashimoto N; Shimoda S; Kawanaka H; Tsuneyama K; Uehara H; Akahoshi T; Kinjo N; Taketomi A; Shirabe K; Akashi K; Lleo A; Ansari AA; Gershwin ME; Maehara Y
    Clin Exp Immunol; 2011 Aug; 165(2):243-50. PubMed ID: 21615390
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.
    Blank C; Gajewski TF; Mackensen A
    Cancer Immunol Immunother; 2005 Apr; 54(4):307-14. PubMed ID: 15599732
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model.
    Okudaira K; Hokari R; Tsuzuki Y; Okada Y; Komoto S; Watanabe C; Kurihara C; Kawaguchi A; Nagao S; Azuma M; Yagita H; Miura S
    Int J Oncol; 2009 Oct; 35(4):741-9. PubMed ID: 19724910
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Preferential contribution of B7-H1 to programmed death-1-mediated regulation of hapten-specific allergic inflammatory responses.
    Tsushima F; Iwai H; Otsuki N; Abe M; Hirose S; Yamazaki T; Akiba H; Yagita H; Takahashi Y; Omura K; Okumura K; Azuma M
    Eur J Immunol; 2003 Oct; 33(10):2773-82. PubMed ID: 14515261
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Negative regulation of T-cell function by PD-1.
    Zha Yy; Blank C; Gajewski TF
    Crit Rev Immunol; 2004; 24(4):229-37. PubMed ID: 15588223
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Human decidual stromal cells suppress cytokine secretion by allogenic CD4+ T cells via PD-1 ligand interactions.
    Nagamatsu T; Schust DJ; Sugimoto J; Barrier BF
    Hum Reprod; 2009 Dec; 24(12):3160-71. PubMed ID: 19729380
    [TBL] [Abstract][Full Text] [Related]  

  • 71. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells.
    Tseng SY; Otsuji M; Gorski K; Huang X; Slansky JE; Pai SI; Shalabi A; Shin T; Pardoll DM; Tsuchiya H
    J Exp Med; 2001 Apr; 193(7):839-46. PubMed ID: 11283156
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Expression of Programmed Death-Ligand 1 by Human Colonic CD90
    Beswick EJ; Grim C; Singh A; Aguirre JE; Tafoya M; Qiu S; Rogler G; McKee R; Samedi V; Ma TY; Reyes VE; Powell DW; Pinchuk IV
    Front Immunol; 2018; 9():1125. PubMed ID: 29910803
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cryopreservation decreases receptor PD-1 and ligand PD-L1 coinhibitory expression on peripheral blood mononuclear cell-derived T cells and monocytes.
    Campbell DE; Tustin NB; Riedel E; Tustin R; Taylor J; Murray J; Douglas SD
    Clin Vaccine Immunol; 2009 Nov; 16(11):1648-53. PubMed ID: 19726615
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.
    Pilon-Thomas S; Mackay A; Vohra N; Mulé JJ
    J Immunol; 2010 Apr; 184(7):3442-9. PubMed ID: 20194714
    [TBL] [Abstract][Full Text] [Related]  

  • 75. B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis.
    Mazanet MM; Hughes CC
    J Immunol; 2002 Oct; 169(7):3581-8. PubMed ID: 12244148
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice.
    Ansari MJ; Salama AD; Chitnis T; Smith RN; Yagita H; Akiba H; Yamazaki T; Azuma M; Iwai H; Khoury SJ; Auchincloss H; Sayegh MH
    J Exp Med; 2003 Jul; 198(1):63-9. PubMed ID: 12847137
    [TBL] [Abstract][Full Text] [Related]  

  • 77. PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells.
    Parekh VV; Lalani S; Kim S; Halder R; Azuma M; Yagita H; Kumar V; Wu L; Kaer LV
    J Immunol; 2009 Mar; 182(5):2816-26. PubMed ID: 19234176
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Roles of programmed death-1 (PD-1)/PD-1 ligands pathway in the development of murine acute myocarditis caused by coxsackievirus B3.
    Seko Y; Yagita H; Okumura K; Azuma M; Nagai R
    Cardiovasc Res; 2007 Jul; 75(1):158-67. PubMed ID: 17434153
    [TBL] [Abstract][Full Text] [Related]  

  • 79. PD-L1 enhances CNS inflammation and infarct volume following experimental stroke in mice in opposition to PD-1.
    Bodhankar S; Chen Y; Vandenbark AA; Murphy SJ; Offner H
    J Neuroinflammation; 2013 Sep; 10():111. PubMed ID: 24015822
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Prevention of experimental autoimmune encephalomyelitis by transfer of embryonic stem cell-derived dendritic cells expressing myelin oligodendrocyte glycoprotein peptide along with TRAIL or programmed death-1 ligand.
    Hirata S; Senju S; Matsuyoshi H; Fukuma D; Uemura Y; Nishimura Y
    J Immunol; 2005 Feb; 174(4):1888-97. PubMed ID: 15699115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 74.